Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty

Angiology

Volumn 52, Issue 10, 2001, Pages 659-669

  Schweizer, J ^a   Muller A ^a   Forkmann, L ^a   Hellner, G ^a   Kirch, W ^a  

^a KLINIKUM CHEMNITZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; CORTICOSTEROID; CYTOSTATIC AGENT; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY DISSECTION; ARTICLE; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPARINIZATION; HUMAN; LEG ARTERY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PELVIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STENOSIS; TREATMENT OUTCOME;

EID: 0034788631     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970105201002     Document Type: Article

References (38)

1. Clinical trials of restenosis after coronary angioplasty
2. Langzeitbeobachtung nach perkutaner transluminaler Angioplastie (PTA) im Becken- und Beinbereich
3. Restenosis: The clinical issues
4. Early rethrombosis in femoropopliteal occlusions treated with percutaneous transluminal angioplasty
5. Migration of smooth muscle and endothelial cells: Critical events in restenosis
6. Antiplatelet agents in the prevention and therapy of thrombosis
7. Prävention der reokklusion
8. Restenoseprophylaxe nach gefaßintervention
9. Restenosis following percutaneous revascularization - The potential role of thrombin and the thrombin receptor
10. Pharmacological approaches to the prevention of restenosis following angioplasty
11. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at 6 months
12. Effects of highdose verapamil on restenosis after peripheral angioplasty
13. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition
14. Low-molecular-weight heparins
15. Low-molecular-weight heparin versus regular heparin or aspirin in the treatment of unstable and silent ischemia
16. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
17. Dose-ranging trial of enoxaparin for unstable angina results of TIMI 11A
18. Anticoagulation: The old and the new
19. Dose-dependent decrease of the rate of restenosis of stents in peripheral vessels with reviparin
20. Low-molecular-weight heparin in prevention of restenosis after angioplasty: Results of Enoxaparin Restenosis (ERA) Trial
21. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: The EMPAR Study
22. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: The FACT study
23. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin
24. Low-molecular-weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs
25. Efficacy of low-molecular-weight heparin delivery with the dispatch catheter following balloon angioplasty in the rabbit iliac artery
26. Arterial heparin sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo
27. Low molecular weight heparin's mechanism of action. Pharmacological profile and product differentiation
28. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
29. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at 6 months
30. Platelet glycoprotein IIb-IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
31. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
32. An international, randomized controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin or both in unstable angina
33. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
34. Randomised placebo-controlled and balloon- angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
35. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
36. Adjuvanter einsatz des monoklonalen antikörpers c7E3 Fab bei peripherer arterieller thrombolyse
37. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis: A pilot study
38. Gefässdissektion nach peripherer angioplastie